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Background: Approximately 80% of Merkel cell carcinomas (MCCs) harbor Merkel cell polyomavirus (MCPyV)
which monoclonally integrates into the genome and has prognostic significance. The presence or absence of
MCPyV is usually diagnosed using CM2B4 immunohistochemistry (IHC) for MCPyV-large T antigen (LT) protein.
However, this method poses a risk of misdiagnosis.
Methods: In this study, we determined MCPyV infection in MCCs using real-time PCR for MCPyV-LT DNA and
prepared 16 cases of MCPyV-DNA-positive and -negative groups. Diagnostic sensitivity and specificity of
conventional PCR for MCPyV-small T antigen (MCPyV-ST), IHC using a newly developed polyclonal antibody
(ST-1) for MCPyV-ST protein (MCPyV-ST) (aa: 164–177), and in situ hybridization (ISH) as well as real-time PCR for
MCPyV-ST mRNA were compared against CM2B4-IHC for sensitivity (0.94, 15/16) and specificity (0.94, 15/16).
Results: The followings are the respective sensitivity and specificity results from examinations for MCPyV-ST gene:
conventional PCR for the MCPyV-ST (0.94, 1.0), ST-1-IHC (0.69, 1.0), real-time PCR for ST mRNA (1.0, no data), ST
mRNA ISH (0.94, 1.0). Each of the MCPyV-pseudonegative (1/16) and -pseudopositive (1/16) diagnoses evaluated
using CM2B4-IHC were accurately corrected by examinations for MCPyV-ST or its expression as well as real-time
PCR for MCPyV-LT. Sensitivity of CM2B4-IHC (0.94) was superior to that of ST-1-IHC (0.69) but equal to that of
ST mRNA-ISH (0.94). Specificities of ST-1-IHC (1.0) and ST mRNA-ISH (1.0) were superior to that of CM2B4-IHC (0.94).
Conclusions: Therefore, combined application of ST mRNA-ISH and ST-IHC as well as CM2B4-IHC is recommended
and will contribute to the diagnostic accuracy for MCPyV infection in MCCs.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/9966295741144834
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Merkel cell carcinoma (MCC) is a rare and aggressive
neuroendocrine skin cancer and Merkel cell polyomavirus
(MCPyV) is monoclonally integrated into the genome of
approximately 80% of MCCs [1]. The MCPyV genome
contains smallT antigen (ST) and largeT antigen (LT) that* Correspondence: hayashik@med.tottori-u.ac.jp
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article, unless otherwise stated.encode nonstructural proteins and are responsible for
viral replication and viral proteins (VPs) that constitute
viral particles [2]. Although the exact pathogenesis has
not yet been elucidated in MCCs, it is considered that
pathogenesis of MCPyV-positive and -negative MCCs is
different [2-5]. Moreover, MCPyV-positive MCCs are
reported to have a better prognosis than MCPyV-negative
MCCs [6-10], although these findings are some con-
troversial [11]. Therefore, accurate diagnosis of thetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Immunohistochemistry (IHC) using a monoclonal anti-
body CM2B4 that detects MCPyV-LT protein (MCPyV-
LT) is currently the most common and prevailed method
for diagnosis of MCPyV infection in MCCs, although real-
time PCR is the most reliable method for confirming
MCPyV-DNA and MCPyV infection in MCCs. The only
commercially available antibody used for MCPyV in-
fection diagnosis is CM2B4 antibody. IHC with
CM2B4 antibody displays high sensitivity and good
specificity for MCPyV detection and is usually suffi-
cient for practical diagnosis, but it is not ideal for de-
termining the presence or absence of MCPyV, based
on reported MCC cases with pseudonegative and
pseudopositive staining [3,12-14]. The ST gene har-
bors fewer mutations than the LT gene in MCPyV
from MCCs [15], and the MCPyV-ST protein (MCPyV-
ST) was detected in human MCC tumors more com-
monly than was MCPyV LT [16].
In this study, we aimed to raise the diagnostic ac-
curacy in determining MCPyV infection in MCCs and
developed a new polyclonal antibody (ST-1) for de-
tecting MCPyV-ST (aa: 164–177) and established a
new in situ hybridization (ISH) as well as real-time PCR
for MCPyV-ST mRNA expression. The sensitivity and
specificity of the newly developed methods to detect
MCPyV-ST expressions were compared with those of
CM2B4-IHC.Materials and methods
MCC samples
We used 32 formalin fixed paraffin embedded (FFPE)
MCC samples from 13 Japanese (MCPyV-positive: 10,
MCPyV-negative: 3, from 1998 to 2008) and 19 Cauca-
sians from the UK (MCPyV-positive: 6, MCPyV-
negative: 13, from 1994 to 2007).Detection of MCPyV-DNA and quantification of MCPyV-ST
mRNA expression
Real-time PCR was performed as previously described
to detect and quantify MCPyV-LT DNA [13,17]. In
addition, conventional PCR was performed using ST
primer sets to detect MCPyV-ST DNA [14]. To quan-
tify expression of MCPyV-ST mRNA, we used the
Universal Probe Library Human TBP Gene Assay
(Roche, Switzerland) as an internal control. After con-
verting RNAs to cDNAs, cDNA fragments from MCPyV-
ST mRNA and control TBP gene were amplified by
real-time PCR using the following primer sets and
probe: qST forward primer; 5′-AGTGTTTTTGCTAT
CAGTGCTTTATTCT-3′, qST reverse primer; 5′-CC
ACCAGTCAAAACTTTCCCA-3′ and fluorogenic ST
probe; 5′-FAM-TGGTTTGGATTTCCTC-MGB-3′.IHC for MCPyV-LT detection
IHC with CM2B4 antibody (Santa Cruz Biotechnology,
Inc. Dallas, TX, USA) was performed using a polymer-
based method to detect MCPyV-LT [13,14].ST antibody (ST-1) manufacturing and IHC for MCPyV-ST
detection
We established a Japanese MCPyV consensus sequence
(DDBJ, Accession number: AB811689). Based on this
MCPyV consensus sequence, we synthesized 164–177
amino acids and manufactured a rabbit polyclonal affinity
purified antibody against MCPyV-ST (ST-1).
Staining protocol for ST-1 is the same as the one used
for LT antibody (CM2B4) except for the primary and
secondary antibodies. We used our primary antibody
(ST-1, dilution 1/5000) and peroxidase-conjugated goat
anti–rabbit IgG as a secondary antibody.ST probe and protocol for ISH
Probe against MCPyV-ST (nt 196–756) was produced
using the CUGA ® 7 in vitro Transcription Kit (NIPPON
GENE, Japan). Instead of 100 mM CTP, 100 mM UTP
and 100 mM ATP provided in the kit, we used the DIG
RNA Labeling Mix (Roche, Switzerland). We followed
Kit manual and the ST probe was electrophoresed and
verified as one band.
The IsHyb In Situ Hybridization (ISH) kit (BioChain,
USA) and TSA PLUS DNP (HRP) SYSTEM (Perkin
Elmer, USA) were used for ISH and we followed the user
manuals. The protocol is described briefly as follows:
After deparaffinization and rehydration, endogenous
peroxidase activity was blocked using 3% hydrogen per-
oxide in methanol for 5 minutes (min). The slides were
fixed with 4% paraformaldehyde in diethylpyrocarbonate
(DEPC) –PBS at room temperature (RT) for 20 min.
Slides were then washed the twice with DEPC–PBS at
RT for 5 min, treated with 10 μg/ml proteinase K at 37°C
for 10 min, washed once in DEPC–PBS at RT for 5 min,
and fixed them again with 4% paraformaldehyde in DEPC–
PBS for 15 min. Following fixation, the slides were rinsed
once with DEPC–water, pre-hybridized with ready-to-use
pre-hybridization solution for 4 hours at 50°C, and hy-
bridized using digoxingenin labeled probe (3 ng/μl) in a
hybridization solution for overnight (8 to16 hours) at 45°C.
After washing in Saline Sodium Citrate (SSC) buffer, the
slides were blocked in Tris-NaCl-blocking (TNB) buffer
for 30 min at RT, incubated slides with Anti-Digoxigenin-
peroxidase (POD), Fab fragments (Roche, Switzerland) for
2 hours at RT, washed in Tris-NaCl-Tween (TNT) buffer 3
times for 5 min at RT, incubated in dinitrophenyl (DNP)
Amplification Reagent working solution for 10 min at RT,
and washed in TNT again. The slides were incubated in
anti–DNP–Horseradish Peroxidase (HRP) for 30 min at
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for colorization, and counterstained with hematoxylin.
Results
Detection of MCPyV-LT or -LT




































NA, noReal-time PCR data were summarized in Table 1.








C32 66 M 1.20 +
C33 66 M 1.48 +
C36 87 F 0.20 +
C37 73 F 0.87 +
C47 90 M 0.06 +
C65 NA F 1.50 +
C68 NA M 11.94 +
C70 NA M 14.40 +
C72 72 F 0.99 +
C74 62 M 0.20 +
UK9 69 M 65.62 +
UK11 61 F 3.81 -
UK16 63 F 127.24 +
UK19 85 F 93.19 +
K21 46 F 51.82 +
UK22 74 F 178.81 +
C50 82 M - -
C63 NA M - -
C64 NA F - f+
UK1 81 F - -
UK2 81 F - -
UK3 85 F - -
UK4 93 F - -
UK6 82 M - -
UK8 87 F - -
UK10 94 F - -
UK12 80 M - -
UK13 61 M - -
UK14 86 F - -
UK15 83 F - -
UK17 83 F - -
UK18 94 F - -
viations: IHC immunohistochemistry, ISH in situ hybridization.
t available; ND, not done; *, copies per cell; f+, focally positive.and -negative groups based on the real-time PCR
data of MCPyV-LT. In 16 MCPyV DNA-positive
MCCs, MCPyV-LT viral copy numbers ranged
from 0.06 to178.81 copies/cell.
2) Immunohistochemical detection of MCPyV-LT
The IHC results using CM2B4 were shown in
Table 1 and representative cases were illustrated in
Figure 1. MCPyV DNA-positive MCCs were
immunoreactive for CM2B4 antibody except for one
case (MCC UK11, left side of Figure 2, Figure 2C forpositive and -negative MCCs
MCPyV-ST
-DNA ST-mRNA IHC (ST-1)
tional PCR Real-time PCR* ISH Nuclear Cytoplasm
+ 2.11 + ++ ++
+ 0.57 + + ++
+ 4.84 + + -
+ 1.97 + - ++
+ 3.13 + - +
+ 2 + + +
+ 13.29 + - +
+ 4.03 + ++ +
+ 2.62 + - +
- 3.14 + - +
+ 0.96 f+ + -
+ 6.97 f+ + ++
+ 8.16 + + ++
+ 1.11 + + ++
+ 6.6 - ++ ++
+ 1.68 + + +
- ND - - +
- ND - - ++
- - - - +
- ND - - +
- ND - - ++
- ND - - +
- ND - - +
- ND - - ++
- ND - - +
- ND - - ++
- ND - - +
- ND - - ++
- ND - - ++
- ND - - ++
- ND - - +
- ND - - ++
Figure 1 Representative histology, immunohistochemistry and ISH of MCPyV-positive MCCs and -negative MCCs. MCPyV-positive MCC
(A) showed immunoreactivity for CM2B4 (MCPyV-LT) (C), whereas MCPyV-negative MCC (B) was negative for CM2B4 (D). There were two MCPyV-ST
positive patterns in MCPyV-positive MCCs; 1) Nuclear immunoreactivity for ST-1 (MCPyV-ST) (E-1) and 2) Nuclear and cytoplasmic immunostaining for
ST-1 (E-2), whereas MCPyV-negative MCCs showed nuclear negativity and nonspecific cytoplasmic staining (F). Nuclear positivity for ISH (MCPyV-ST
mRNA) was observed in MCPyV-positive MCCs (G), but no positive staining was detected in MCPyV-negative MCCs (H). A and B, H and E stain;
A through H, original magnification × 400.
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amplified using conventional PCR (ST-DNA) and
using real-time PCR (LT-DNA; 3.81 copies/cell).
MCPyV DNA-negative MCCs were negative for
CM2B4 but one case (MCC64, right side of Figure 2)
was focally CM2B4-positive (Figure 2D). As shown
in Figure 2, these two cases of MCC UK11 and
MCC64 examined by CM2B4-IHC wereMCPyV-pseudonegative and -pseudopositive
MCCs, respectively (Figure 2).Detection of MCPyV-ST, −ST or -ST mRNA
1) MCPyV-ST detection by conventional PCR
As shown in Table 1, MCPyV-ST DNA was
amplified using conventional PCR in MCPyV
Figure 2 MCPyV-pseudonegative [CM2B4 (−) and MCPyV-DNA (+)] and -pseudopositive [CM2B4 (+) and MCPyV-DNA (−)] MCCs. MCC
UK11 case (A) was negative for MCPyV-LT (CM2B4) (C) despite the presence of MCPyV-DNAs (LT-DNA; 3.81 copies/cell) and was positive for
MCPyV-ST immunoreactivity (ST-1) (E) and -ST mRNA expression by ISH (G). CM2B4-positive MCC64 (B) had no MCPyV-DNAs and showed no
expression of ST-1 (F) and ST mRNA (H). A and B, H and E stain; A through H, original magnification × 400.
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(15/16, 94%) but not in the MCPyV LT-negative
group (0/16).
2) Immunohistochemical detection of MCPyV-ST
The IHC results using ST-1 were shown in Table 1
and representative cases were illustrated in Figure 1E.
Nuclear ST (ST-1 antibody)-immunoreactivity was
observed in 11 of 16 MCPyV DNA-positive MCCs
(69%) but not in any of 16 MCPyV DNA-negativeMCCs (0/16, 0%). Cytoplasmic ST-1 immunostaining
was observed in all MCPyV DNA-positive
and -negative MCCs, except two MCPyV
DNA-positive cases (MCC36 and MCC UK9), which
showed only nuclear immunoreactions (Figure 1E-1).
Nine of 11 nuclear ST-1 positive cases in MCPyV
DNA-positive MCCs also showed some extent of
cytoplasmic ST-1 reaction (Figure 1E-2). These
findings suggest that nuclear ST-1 immunostaining is
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nonsignificant. The respective sensitivity and
specificity of ST-1 nuclear and cytoplasmic reactions
were as follows: Evaluation for nuclear reaction:
sensitivity, 0.69 (11/16 DNA-positive cases);
specificity, 1.0 (0/16 DNA-negative cases) and
evaluation for cytoplasmic reaction: sensitivity,
0.88 (14/16 DNA-positive cases); specificity, 0
(16/16 DNA-negative cases).
3) Quantification of ST mRNA using real-time PCR
and detection of ST mRNA expression using ISH
ST mRNA was quantified using real-time PCR only
in all MCPyV DNA-positive cases and ranged from
0.57 to 13.29 copies /cell, but was undetectable in
the MCPyV DNA-negative cases (Table 1).
ISH data for ST mRNA expression were shown in
Table 1. A representative ST mRNA-positive case was
indicated in Figure 1G. A nuclear ST mRNA-positive
signal was observed in 15 of 16 MCPyV DNA-positive
cases (sensitivity: 0.94) and in no MCPyV DNA-negative
cases (0/16; specificity: 1.0, Figure 1H).
In MCPyV DNA-positive MCC cases, the frequency of
ST mRNA expression by ISH (15/16, 94%) was higher than
that of ST-1 nuclear expression (11/16, 69%). ST mRNA
expression data by ISH did not necessarily correspond to
the quantity of ST mRNA using real-time PCR or ST-1
nuclear immunoreaction data by IHC.
Detailed comparisons of sensitivity and specificity in
all kinds of examinations for detecting MCPyV infection
in MCCs were summarized in Table 2.
Correction of MCPyV-pseudonegative (CM2B4-negative
and LT DNA-positive) and MCPyV-pseudopositive
(CM2B4-positive and LT DNA-negative) cases by ST
mRNA-ISH and ST-IHC
Figure 2 illustrates an MCPyV-pseudonegative case (MCC
UK11, left side) and MCPyV-pseudopositive case (MCC64,
right side), which were reconfirmed as MCPyV-positiveTable 2 Comparison of sensitivity and specificity among
real-time PCR, conventional PCR, IHC and ISH for
detecting MCPyV-infection
Target gene Kinds of examinations Sensitivity Specificity
MCPyV-LT
Real-time PCR 1.0 1.0
IHC (CM2B4) 0.94 0.94
MCPyV-ST
Conventional PCR for ST DNA 0.94 1.0
IHC (ST-1)
Nuclear reaction 0.69 1.0
Cytoplasmic reaction 0.88 0
Real-time PCR for ST mRNA 1.0 ND
ISH for ST mRNA 0.94 1.0and -negative, respectively, by ST mRNA-ISH and ST-IHC.
Sensitivity of CM2B4-IHC (0.94, 15/16) was superior to
that of ST-IHC (0.69, 11/16) but equal to the sensitivity of
ST mRNA-ISH (0.94, 15/16). Therefore, combined applica-
tion of ST mRNA-ISH and ST-IHC as well as CM2B4-IHC
is recommended and will contribute to the better and pre-
cise diagnosis of MCPyV infection in MCCs.
Discussion
To detect MCPyV-LT, IHC along with a monoclonal anti-
body, CM2B4, is commonly used by several pathologists
and researchers to determine infection in MCCs [14,18].
However, Kuwamoto et al. [13] pointed imperfect in sen-
sitivity and specificity of CM2B4. Some researchers also
reported CM2B4-pseudonegative or -pseudopositive MCC
cases that were immunonegative for CM2B4 despite the
detection of MCPyV-DNA using conventional PCR or
real-time PCR [3,12,14] or immunopositive for CM2B4
despite no detection of MCPyV-DNA using conventional
PCR and real-time PCR [13]. The CM2B4 antibody is
extremely useful but not ideal in both sensitivity and spe-
cificity to determine accurate MCPyV infection in MCCs,
because CM2B4 IHC data were not necessarily compatible
with those of real-time PCR, which is the most reliable
method. Recently, Leitz et al. [19] also emphasized that
combined use of ST-specific antibody or a more sensitive
LT-specific antibody (Ab3) and PCR using multiple primer
pairs need to be applied to increase sensitivity, because
CM2B4 IHC does not detect all MCPyV-positive
MCC cases.
In this study, we prepared each 16 cases of MCPyV-
DNA-positive and -negative MCCs which were deter-
mined by real-time PCR for MCPyV-LT. The sensitivity
and specificity in all methods used in this study to detect
MCPyV-ST DNA, −ST mRNA or -ST were summarized
in Table 2, comparing with those of the popularized
CM2B4 IHC. MCPyV-ST DNA was detected in 15 of the
total 32 MCC cases (15/16 MCPyV-LT DNA-positive
MCCs) using conventional PCR with the ST primers
(sensitivity, 0.94; specificity, 1). Differences in the sensi-
tivity of real-time or conventional PCR with the different
primers may be caused by some mutations in the target
region, making amplification of DNA fragments difficult.
ST-1 antibody, which was newly developed to detect
MCPyV-ST (aa: 164–177), was immunoreactive for the
nuclei and/or cytoplasm of MCC tumor cells. According
to the sensitivity and specificity data of ST-1 IHC (Nuclear
reaction: sensitivity, 0.69, specificity, 1.0; cytoplasmic reac-
tion: sensitivity, 0.875, specificity, 0), evaluation of nuclear
ST (ST-1 antibody)-immunoreactivity was significant and
useful for diagnosis of MCPyV-infected MCCs but cyto-
plasmic ST immunoreactivity was not significant. Shuda
et al. also reported [16] that expression of MCPyV-ST was
detected in both nuclei and cytoplasm by IHC. MCPyV-
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located between the retinoblastoma protein (RB)-binding
and DNA helicase domains [20]. Therefore, nuclear LT
(CM2B4 antibody)-immunoreactivity is evaluated as sig-
nificant. On the other hand, NLS of MCPyV-ST region
has not been revealed until now. Therefore, it may be pos-
sible that cytoplasmic staining of MCPyV-positive MCCs
may be a partly true immunoreaction, although cyto-
plasmic immunoreactions in both MCPyV-positive MCCs
and -negative MCCs suggest that they are not significant.
In each case of MCPyV-pseudonegative (MCC UK11)
or -pseudopositive (MCC64) MCC determined by CM2B4
IHC, nuclear ST-1 imunoreactivity corresponded to the
data of real-time PCR for LT-DNA, conventional PCR for
ST-DNA, and real-time PCR or ISH for ST mRNA. This
was useful for correcting the misdiagnosis for MCPyV
infection evaluated by CM2B4 IHC. As another method
of detecting MCPyV-ST mRNA expression, we developed
a new ISH approach using the ST probe recognizing
MCPyV-ST (nt: 196–756). ISH revealed nuclear positive
staining demonstrated in all MCPyV-positive MCCs
except in one case (sensitivity, 0.94; specificity, 1.0). This
ISH is also a good method and the first application to
detect the MCPyV infection in FFPE samples of MCCs.
The reason why one ST mRNA could not be detected by
ISH was because of the old issue of FFPE. Real-time PCR
for quantifying ST mRNA expression demonstrated the
best sensitivity (1.0) and is comparable with the sensitivity
(1.0) of real-time PCR for LT DNA. However, quantities of
MCPyV-ST mRNA expression using real-time PCR in
MCPyV-infected MCCs did not necessarily correlate with
the expression levels of ST mRNA-ISH or ST-1 IHC. With
regard to the studies of MCCs, MCPyV-LT is the main
analytic region in the studies of MCPyV-infected MCCs
because MCPyV-DNA with truncated mutations in the LT
region is integrated into the MCC host genome [21]. The
interaction of MCPyV-LT and RB [22] is essential for sus-
taining tumor growth. A recent study [16] indicated that
MCPyV-ST expression was required for the Merkel cell
tumor growth in vitro and was observed to act down-
stream in the mammalian target of rapamycin (mTOR)
signaling pathway to preserve eukaryotic translation
initiation factor 4E-binding protein 1 (4E-BP1) hyper-
phosphorylation, resulting in dysregulated cap-dependent
translation and that 4E-BP1 inhibition is required for
MCPyV transformation. The function of MCPyV-ST has
not been fully elucidated and in order to analyze this in
the future, ST-1 IHC and ST mRNA-ISH will be useful
methods.
Conclusion
In conclusion, we emphasize again that in order to pre-
cisely determine MCPyV infection of MCCs, combined
application of ST-1 IHC and ST mRNA-ISH as well asCM2B4 IHC is recommended and will contribute to a
better and accurate diagnosis for MCPyV infection in
MCCs.
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